Setrusumab (BPS 804) is a fully humanized monoclonal antibody targeting sclerostin, effectively enhancing bone strength, used in research on Osteogenesis Imperfecta (OI) and cancer [1].
CAS Number:
[1847394-95-9]
Target:
Wnt/beta-catenin
* VAT and and shipping costs not included. Errors and price changes excepted